![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: Everest Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 11, 2022